|
【结 构 式】 
|
【分子编号】19646 【品名】1-[([[(phenoxycarbonyl)oxy]amino]carbonyl)oxy]benzene 【CA登记号】 |
【 分 子 式 】C14H11NO5 【 分 子 量 】273.24508 【元素组成】C 61.54% H 4.06% N 5.13% O 29.28% |
合成路线1
该中间体在本合成路线中的序号：(IX)Ether (III) was prepared by condensation of (S)-4-(hydroxymethyl)butyrolactone (I) and 4-fluorophenol (II) in the presence of diisopropylazodicarboxylate (DIAD) and triphenylphosphine under Mitsunobu conditions. Then, reduction of lactone (III) with DIBAL-H in toluene at -78 C gave lactol (IV), which was converted to silyl ether (V) by treatment with tert-butyldimethylsilyl chloride (TBDMS-Cl) and imidazole. Subsequent reaction of (V) with TBDMS-Br in CH2Cl2 at -78 C, followed by condensation with the lithium acetylide derived from acetylene (VI), yielded compound (VII) as a mixture of isomers. Chromatographic separation of the mixture provided the desired trans isomer, which was deprotected by treatment with tetra-n-butylammonium fluoride to give alcohol (VIII). This was then condensed with N,O-bis(phenoxycarbonyl)hydroxylamine (IX) in the presence of DIAD and Ph3P to furnish the hydroxamic acid derivative (X). Finally, concomitant deprotection of the O-phenoxycarbonyl group and substitution of the remaining phenoxy group for an amino group by treatment with methanolic ammonia in a pressure tube, provided the title compound.
| 【1】 Cai, X.; Grewal, G.; Hussoin, S.; Fura, A.; Scannell, R.; Biftu, T.; Qian, C. (CytoMed, Inc.); Cpds. and methods for the treatment of cardiovascular, inflammatory and immune disorders. JP 1998506096; US 5703093; US 5792776; WO 9600212 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 46090 | (5R)-5-(hydroxymethyl)dihydro-2(3H)-furanone | C5H8O3 | 详情 | 详情 | |
| (II) | 19639 | 4-fluorophenol | 371-41-5 | C6H5FO | 详情 | 详情 |
| (III) | 19640 | (5S)-5-[(4-fluorophenoxy)methyl]dihydro-2(3H)-furanone | 175212-40-5 | C11H11FO3 | 详情 | 详情 |
| (IV) | 19641 | (5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanol | C11H13FO3 | 详情 | 详情 | |
| (V) | 19642 | tert-butyl(dimethyl)silyl (5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl ether; tert-butyl([(5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl]oxy)dimethylsilane | C17H27FO3Si | 详情 | 详情 | |
| (VI) | 19643 | tert-butyl(dimethyl)silyl 3-butynyl ether; tert-butyl(3-butynyloxy)dimethylsilane | C10H20OSi | 详情 | 详情 | |
| (VII) | 19644 | tert-butyl(dimethyl)silyl 4-[(5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl]-3-butynyl ether; tert-butyl[(4-[(5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl]-3-butynyl)oxy]dimethylsilane | C21H31FO3Si | 详情 | 详情 | |
| (VIII) | 19645 | 4-[(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl]-3-butyn-1-ol | C15H17FO3 | 详情 | 详情 | |
| (IX) | 19646 | 1-[([[(phenoxycarbonyl)oxy]amino]carbonyl)oxy]benzene | C14H11NO5 | 详情 | 详情 | |
| (X) | 19647 | (2S,5S)-2-[(4-fluorophenoxy)methyl]-5-(4-[(phenoxycarbonyl)[(phenoxycarbonyl)oxy]amino]-1-butynyl)tetrahydrofuran | C29H26FNO7 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(XX)Intermediate (XVI) is treated with BuLi and diisopropylamine in THF giving the chiral acetylenic tetrahydrofuran (XVII). The addition of ethylene oxide (XVIII) to the terminal acetylene of (XVII) by means of BF3/Et2O in THF gives the 3-butyl-1-ol derivative (XIX), which is condensed with N,O-bis(phenoxy- carbonyl)hydroxylamine (XX) by means of PPh3 and diisopropylazodicarboxylate (DIAD) in THF yielding the final intermediate (XXI). Finally, this compound is treated with ammonia in methanol to obtain the target urea derivative.
| 【1】 Adhikari, S.S.; Hymavathi, L.; Sadalapure, K.; Sharma, G.V.M.; Sreenivas, P.; Mhaskar, S.V.; Lalitha, S.V.S.; Chorghade, M.S.; Murugaiah, A.M.S.; Prasad, T.R.; Reddy, B.S.; Gurjar, M.K.; Reddy, V.G.; Krishna, P.R. (LeukoSite, Inc.); Substd. oxygen alicyclic cpds., including methods for synthesis thereof. WO 0001381 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XVI) | 32994 | (1R)-3-[(2R,3R)-3-(chloromethyl)oxiranyl]-1-[(4-fluorophenoxy)methyl]propyl benzenesulfonate | C19H20ClFO5S | 详情 | 详情 | |
| (XVII) | 32995 | [(2S,5S)-5-ethynyltetrahydro-2-furanyl]methyl 4-fluorophenyl ether; (2S,5S)-2-ethynyl-5-[(4-fluorophenoxy)methyl]tetrahydrofuran | C13H13FO2 | 详情 | 详情 | |
| (XVIII) | 10393 | Oxirane; Ethylene oxide | 75-21-8 | C2H4O | 详情 | 详情 |
| (XIX) | 19645 | 4-[(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl]-3-butyn-1-ol | C15H17FO3 | 详情 | 详情 | |
| (XX) | 19646 | 1-[([[(phenoxycarbonyl)oxy]amino]carbonyl)oxy]benzene | C14H11NO5 | 详情 | 详情 | |
| (XXI) | 19647 | (2S,5S)-2-[(4-fluorophenoxy)methyl]-5-(4-[(phenoxycarbonyl)[(phenoxycarbonyl)oxy]amino]-1-butynyl)tetrahydrofuran | C29H26FNO7 | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号：(IX)The reaction of oxirane (I) with vinylmagnesium bromide in THF gives 1-(4-fluorophenoxy)-4-penten-2(S)-ol (II), which is treated with ethyl vinyl ether and mercuric trifluoroacetate to yield the vinyl ether (III). The cyclization of (III) by means of Grubb's catalyst in refluxing benzene affords the dihydrofuran (IV), which is treated with benzenesulfinic acid in dichloromethane to give the sulfone (V). The reaction of (V) with the acetylenic tetrahydropyranyl ether (VI) by means of isopropylmagnesium bromide in THF yields the expected addition product (VII), which is treated with TsOH to eliminate the tetrahydropyranyl group and provide the alcohol (VIII). The condensation of (VIII) with N,O-bis (phenoxycarbonyl)hydroxylamine (IX) by means of PPh3 and DEAD in THF affords the protected carbamate derivative (X), which is finally treated with ammonia in methanol.
| 【1】 Gurjar, M.K.; et al.; A versatile approach to anti-asthmatic compound CMI-977 and its six-membered analogue. Synthesis 2000, 4, 557. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| 16524 | bromo(vinyl)magnesium | 1826-67-1 | C2H3BrMg | 详情 | 详情 | |
| 18762 | 1-Ethoxyethylene; Ethyl vinyl ether；Ethoxyethene | 109-92-2 | C4H8O | 详情 | 详情 | |
| 40726 | dioxo(phenyl)-lambda(6)-sulfane | C6H6O2S | 详情 | 详情 | ||
| (I) | 32986 | 4-fluorophenyl (2S)oxiranylmethyl ether; (2S)-2-[(4-fluorophenoxy)methyl]oxirane | 108648-25-5 | C9H9FO2 | 详情 | 详情 |
| (II) | 38536 | (2S)-1-(4-fluorophenoxy)-4-penten-2-ol | C11H13FO2 | 详情 | 详情 | |
| (III) | 38537 | (1S)-1-[(4-fluorophenoxy)methyl]-3-butenyl vinyl ether; 1-fluoro-4-[[(2S)-2-(vinyloxy)-4-pentenyl]oxy]benzene | C13H15FO2 | 详情 | 详情 | |
| (IV) | 38538 | (2S)-2-[(4-fluorophenoxy)methyl]-2,3-dihydrofuran; (2S)-2,3-dihydro-2-furanylmethyl 4-fluorophenyl ether | C11H11FO2 | 详情 | 详情 | |
| (V) | 38539 | (2S,5R)-2-[(4-fluorophenoxy)methyl]-5-(phenylsulfonyl)tetrahydrofuran; (2R,5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl phenyl sulfone | C17H17FO4S | 详情 | 详情 | |
| (VI) | 38540 | 2-(4-pentynyloxy)tetrahydro-2H-pyran; 4-pentynyl tetrahydro-2H-pyran-2-yl ether | 62992-46-5 | C10H16O2 | 详情 | 详情 |
| (VII) | 38541 | 5-[(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl]-4-pentynyl tetrahydro-2H-pyran-2-yl ether; 2-[(5-[(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl]-4-pentynyl)oxy]tetrahydro-2H-pyran | C21H27FO4 | 详情 | 详情 | |
| (VIII) | 19645 | 4-[(2S,5S)-5-[(4-fluorophenoxy)methyl]tetrahydro-2-furanyl]-3-butyn-1-ol | C15H17FO3 | 详情 | 详情 | |
| (IX) | 19646 | 1-[([[(phenoxycarbonyl)oxy]amino]carbonyl)oxy]benzene | C14H11NO5 | 详情 | 详情 | |
| (X) | 19647 | (2S,5S)-2-[(4-fluorophenoxy)methyl]-5-(4-[(phenoxycarbonyl)[(phenoxycarbonyl)oxy]amino]-1-butynyl)tetrahydrofuran | C29H26FNO7 | 详情 | 详情 |
合成路线4
该中间体在本合成路线中的序号：(X)Condensation of 4-methylacetophenone (I) with ethyl diethoxyacetate (II) in the presence of lithium hexamethyldisilazide afforded diketoacetal (III). Formation of pyrazole (V) was accomplished by treatment of (III) with 4-methoxy-phenylhydrazine (IV). Subsequent acid hydrolysis of the diethyl acetal gave aldehyde (VI), which was condensed with carbon tetrabromide using triphenyl phosphine to furnish dibromoethylene compound (VII). Elimination of HBr in (VII) by treatment with tetrabutylammonium fluoride produced bromo-acetylene (VIII). After lithium-bromine exchange, addition of paraformaldehyde yielded the propargyl alcohol (IX). Further Mitsunobu coupling of (IX) with N,O-bis(phenoxycarbonyl)hydroxylamine (X) gave the N,O-bis-protected N-alkyl hydroxylamine (XI). This was finally converted to the title N-hydroxyurea by treatment with methanolic ammonia.
| 【1】 Wetter, S.K.; Connolly, P.J.; Beers, K.N.; et al.; N-Hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase. Bioorg Med Chem Lett 1999, 9, 7, 979. |
| 【2】 Chen, R.; Wachter, M.; Connolly, P. (Ortho-McNeil Pharmaceutical, Inc.); Acetylenic 1,5-diarylpyrazoles as antiinflammatory agents. US 5925769 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 12685 | 4-Chloroacetophenone; 1-(4-Chlorophenyl)-1-ethanone; p-Chloroacetophenone | 99-91-2 | C8H7ClO | 详情 | 详情 |
| (II) | 25674 | ethyl 2,2-diethoxyacetate | 6065-82-3 | C8H16O4 | 详情 | 详情 |
| (III) | 34716 | 1-(4-chlorophenyl)-4,4-diethoxy-1,3-butanedione | C14H17ClO4 | 详情 | 详情 | |
| (IV) | 12688 | 4-Hydrazinophenyl methyl ether; 1-(4-Methoxyphenyl)hydrazine | 3471-32-7 | C7H10N2O | 详情 | 详情 |
| (V) | 34717 | 4-[5-(4-chlorophenyl)-3-(diethoxymethyl)-1H-pyrazol-1-yl]phenyl methyl ether; 5-(4-chlorophenyl)-3-(diethoxymethyl)-1-(4-methoxyphenyl)-1H-pyrazole | C21H23ClN2O3 | 详情 | 详情 | |
| (VI) | 34718 | 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazole-3-carbaldehyde | C17H13ClN2O2 | 详情 | 详情 | |
| (VII) | 34719 | 4-[5-(4-chlorophenyl)-3-(2,2-dibromovinyl)-1H-pyrazol-1-yl]phenyl methyl ether; 5-(4-chlorophenyl)-3-(2,2-dibromovinyl)-1-(4-methoxyphenyl)-1H-pyrazole | C18H13Br2ClN2O | 详情 | 详情 | |
| (VIII) | 34720 | 3-(2-bromoethynyl)-5-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazole; 4-[3-(2-bromoethynyl)-5-(4-chlorophenyl)-1H-pyrazol-1-yl]phenyl methyl ether | C18H12BrClN2O | 详情 | 详情 | |
| (IX) | 34725 | 3-[5-(4-chlorophenyl)-1-(4-methoxyphenyl)-1H-pyrazol-3-yl]-2-propyn-1-ol | C19H15ClN2O2 | 详情 | 详情 | |
| (X) | 19646 | 1-[([[(phenoxycarbonyl)oxy]amino]carbonyl)oxy]benzene | C14H11NO5 | 详情 | 详情 | |
| (XI) | 34726 | 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(3-[(phenoxycarbonyl)[(phenoxycarbonyl)oxy]amino]-1-propynyl)-1H-pyrazole | C33H24ClN3O6 | 详情 | 详情 |
合成路线5
该中间体在本合成路线中的序号：(IX)4-Iodophenol (I) is alkylated with 1,2-dibromoethane (II) to afford 1-(2-bromoethoxy)-4-iodobenzene (III). Subsequent palladium-catalyzed coupling of aryl iodide (III) with 3-butyn-1-ol (IV) furnishes the phenylbutynol adduct (V), which is further hydrogenated in the presence of Pd/C to the saturated alcohol (VI). Condensation of the alkyl bromide (VI) with (R)-p-chlorobenzhydrylpiperazine (VII) produces the dialkylated piperazine (VIII). Then, Mitsunobu coupling of arylbutanol (VIII) with phenoxycarbonylaminophenoxyformate (IX) leads to the protected hydroxamic acid (X). This is finally treated with methanolic ammonia to provide the title N-hydroxyurea derivative.
| 【1】 Chatelain, P.; Differding, E.; Cai, X.; Hussoin, S.; Grewal, G.; Young, M.; Lewis, T.; Toy-Palmer, A.; Scannel, R.; Ellis, J.; Lassoie, M.-A. (UCB SA); Cpds. and methods for treatment of asthma, allergy and inflammatory disorders. JP 2002540198; US 6451801; WO 0058295 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 22242 | 4-iodophenol | 540-38-5 | C6H5IO | 详情 | 详情 |
| (II) | 10252 | 1,2-Dibromoethane; Ethylene dibromide | 106-93-4 | C2H4Br2 | 详情 | 详情 |
| (III) | 64422 | 1-(2-bromoethoxy)-4-iodobenzene; 2-bromoethyl 4-iodophenyl ether | C8H8BrIO | 详情 | 详情 | |
| (IV) | 32507 | 3-butyn-1-ol | 927-74-2 | C4H6O | 详情 | 详情 |
| (V) | 64423 | 4-[4-(2-bromoethoxy)phenyl]-3-butyn-1-ol | C12H13BrO2 | 详情 | 详情 | |
| (VI) | 64424 | 4-[4-(2-bromoethoxy)phenyl]-1-butanol | C12H17BrO2 | 详情 | 详情 | |
| (VII) | 30404 | 1-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazine | C17H19ClN2 | 详情 | 详情 | |
| (VIII) | 64425 | 4-[4-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethoxy)phenyl]-1-butanol | C29H35ClN2O2 | 详情 | 详情 | |
| (IX) | 19646 | 1-[([[(phenoxycarbonyl)oxy]amino]carbonyl)oxy]benzene | C14H11NO5 | 详情 | 详情 | |
| (X) | 64426 | 1-[(R)-(4-chlorophenyl)(phenyl)methyl]-4-{2-[4-(4-{(phenoxycarbonyl)[(phenoxycarbonyl)oxy]amino}butyl)phenoxy]ethyl}piperazine | C43H44ClN3O6 | 详情 | 详情 |
合成路线6
该中间体在本合成路线中的序号：(VIII)Esterification of 5-iodosalicylic acid (I) with methanol and H2SO4 provides the methyl ester (II). Subsequent palladium-catalyzed coupling of (II) with 3-butyn-1-ol (III) yields adduct (IV). Alkylation of the phenolic hydroxyl group of (IV) with 1,2-dibromoethane affords the bromoethyl ether (V). The bromide group of (V) is then displaced with (R)-p-chlorobenzhydryl piperazine (VI) to produce the disubstituted piperazine (VII). Mitsunobu coupling of alcohol (VII) with phenoxycarbonylamino phenoxyformate (VIII) furnishes the protected N-hydroxy carbamate (IX). Finally, ammonolysis of the ester groups of (IX) gives rise to a mixture of the title N-hydroxyurea derivative, along with the analogous methyl ester (X), which can be separated by means of flash chromatography
| 【1】 Chatelain, P.; Differding, E.; Cai, X.; Hussoin, S.; Grewal, G.; Young, M.; Lewis, T.; Toy-Palmer, A.; Scannel, R.; Ellis, J.; Lassoie, M.-A. (UCB SA); Cpds. and methods for treatment of asthma, allergy and inflammatory disorders. JP 2002540198; US 6451801; WO 0058295 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (A) | 10252 | 1,2-Dibromoethane; Ethylene dibromide | 106-93-4 | C2H4Br2 | 详情 | 详情 |
| (I) | 60359 | 2-hydroxy-5-iodobenzoic acid | C7H5IO3 | 详情 | 详情 | |
| (II) | 37875 | methyl 2-hydroxy-5-iodobenzoate | C8H7IO3 | 详情 | 详情 | |
| (III) | 32507 | 3-butyn-1-ol | 927-74-2 | C4H6O | 详情 | 详情 |
| (IV) | 60360 | methyl 2-hydroxy-5-(4-hydroxy-1-butynyl)benzoate | C12H12O4 | 详情 | 详情 | |
| (V) | 60361 | methyl 2-[(2-bromoethyl)oxy]-5-(4-hydroxy-1-butynyl)benzoate | C14H15BrO4 | 详情 | 详情 | |
| (VI) | 30404 | 1-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazine | C17H19ClN2 | 详情 | 详情 | |
| (VII) | 60362 | methyl 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethyl)oxy]-5-(4-hydroxy-1-butynyl)benzoate | C31H33ClN2O4 | 详情 | 详情 | |
| (VIII) | 19646 | 1-[([[(phenoxycarbonyl)oxy]amino]carbonyl)oxy]benzene | C14H11NO5 | 详情 | 详情 | |
| (IX) | 60363 | methyl 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethyl)oxy]-5-[4-([(phenyloxy)carbonyl]{[(phenyloxy)carbonyl]oxy}amino)-1-butynyl]benzoate | C45H42ClN3O8 | 详情 | 详情 | |
| (X) | 60364 | methyl 5-{4-[(aminocarbonyl)(hydroxy)amino]-1-butynyl}-2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethyl)oxy]benzoate | C32H35ClN4O5 | 详情 | 详情 |
合成路线7
该中间体在本合成路线中的序号：(IX)A related method for the synthesis of the title compound has been reported. After esterification of 5-iodosalicylic acid (I), the methyl ester (II) is reacted with 1,2-dibromoethane to give bromide (III). Coupling of aryl iodide (III) with 3-butyn-1-ol (IV) leads to adduct (V). Displacement of bromide (V) with (R)-p-chlorobenzhydryl piperazine (VI) furnishes piperazine (VII). Then, ester group ammonolysis in (VII) leads to amide (VIII). Coupling of alcohol (VIII) with phenoxycarbonylamino phenoxyformate (IX) under Mitsunobu conditions furnishes the protected N-hydroxy carbamate (X). Finally, treatment of (X) with methanolic ammonia provides the desired N-hydroxyurea derivative
| 【1】 Cai, X.; Arrington, M.; Bayless, L.; et al.; Discovery of UCB 35440: A potent and orally active dual acting 5-lipoxygenase inhibitor and H1 receptor antagonist. 224th ACS Natl Meet (Aug 18 2002, Boston) 2002, Abst MEDI 317. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 60359 | 2-hydroxy-5-iodobenzoic acid | C7H5IO3 | 详情 | 详情 | |
| (II) | 37875 | methyl 2-hydroxy-5-iodobenzoate | C8H7IO3 | 详情 | 详情 | |
| (III) | 30366 | 4-(3-Methoxyphenyl)-1,5-dimethyl-4-propyl-1-azoniabicyclo[3,1,0]hexane tetrafluoroborate | C17H26BF4NO | 详情 | 详情 | |
| (IV) | 32507 | 3-butyn-1-ol | 927-74-2 | C4H6O | 详情 | 详情 |
| (V) | 60361 | methyl 2-[(2-bromoethyl)oxy]-5-(4-hydroxy-1-butynyl)benzoate | C14H15BrO4 | 详情 | 详情 | |
| (VI) | 30404 | 1-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazine | C17H19ClN2 | 详情 | 详情 | |
| (VII) | 60362 | methyl 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethyl)oxy]-5-(4-hydroxy-1-butynyl)benzoate | C31H33ClN2O4 | 详情 | 详情 | |
| (VIII) | 60367 | 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethyl)oxy]-5-(4-hydroxy-1-butynyl)benzamide | C30H32ClN3O3 | 详情 | 详情 | |
| (IX) | 19646 | 1-[([[(phenoxycarbonyl)oxy]amino]carbonyl)oxy]benzene | C14H11NO5 | 详情 | 详情 | |
| (X) | 60363 | methyl 2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethyl)oxy]-5-[4-([(phenyloxy)carbonyl]{[(phenyloxy)carbonyl]oxy}amino)-1-butynyl]benzoate | C45H42ClN3O8 | 详情 | 详情 |